-ATPases are large multisubunit proton pumps, which in mammals consist of at least 14 subunits that may be coexpressed with and require additional accessory subunits (12, 26) . H ϩ -ATPases are ubiquitous and essential enzymes that convert the energy from ATP hydrolysis to pumping protons across membranes (12, 26) . Genetic deletion of essential H ϩ -ATPase subunits in mice leads to very early embryonic death at the 4-to 8-cell stage. H ϩ -ATPases are found in the membranes of and acidify intracellular organelles that include the Golgi, lysosomes, and endosomes (12, 21) . However, in some specialized cells H ϩ -ATPases are also expressed at the plasma membrane and participate in intracellular pH control or acidification of the extracellular space. This role is important in osteoclasts, the stria vascularis of the inner ear, macrophages, solid tumors, many different cells along the renal nephron, and the clear cells of the epididymis (6, 13 (13) . Moreover, mice that lack the d2, a3, or B1 subunits have defects in the skin, bone, or kidney (11, 15) . Functional experiments in epididymis revealed that clear cell H ϩ -ATPases have a critical role in regulating the pH of the luminal fluid where sperm is stored: Sperm activation is highly pH dependent and the acidic environment in the epididymis prevents premature activation (7) . Thus proton pumping in the epididymis is important for fertility, and several mouse strains with altered fluid pH or proton pump expression in the epididymis have reduced fertility (5, 23) .
Obviously the activity of proton pumps in the plasma membrane must be tightly regulated. In the kidney the role of many hormonal systems has been explored and intracellular signaling cascades elucidated. These signaling cascades include angiotensin II, aldosterone, cAMP, and protein kinase A as well as calcium and protein kinase-dependent pathways (19 -20, 25, 27-28) . In the epididymis, stimuli that increase plasma membrane expression and activity of H ϩ -ATPase include purinergic receptors, the nitric oxide (NO) and soluble guanylyl cyclase pathway, extracellular bicarbonate and cAMP, and angiotensin II (4, 18, 22) . Activation of these pathways can increase H ϩ -ATPase activity by several mechanisms, the most prominent of which is recycling of pumps into and out of the membrane as evident from studies of kidney, epididymis, or various cell lines (26) . Alternatively, reversible assembly of the two major domains of H ϩ -ATPase, the cytosolic V 1 and the membrane-bound V 0 domains, occurs (13, 21, 26) . Changes in the coupling of ATP hydrolysis to H ϩ -pumping may also occur (13, 17, 21) . Moreover, direct phosphorylation of the A subunit might affect any of the mechanisms mentioned above (1, 9) . Assembly of proton pumps as well as trafficking of pumps requires anchoring to the cytoskeleton and an active remodeling of the actin cytoskeleton. Indeed, the B1, B2, and C subunits can bind to actin, thereby providing a possible physical link between the pump and the cytoskeleton (8, 14, 24) . However, such interactions, as well as the active remodeling of the cytoskeleton, must be actively controlled.
Rho proteins are major regulators of the cytoskeleton in many cell types, and Rho inhibitors have been implicated in the treatment of arteriosclerosis, cancer, and erectile dysfunction (2, 10). Rho proteins are active when bound to GTP and interact with downstream effectors. Hydrolysis of GTP to GDP inactivates Rho proteins, a process controlled by a large number of additional proteins, including guanine-nucleotide-exchange factors (GEFs), GTPase-activating proteins (GAPs), and Rho guanine nucleotide-dissociation inhibitors (GDIs), which control the binding and hydrolysis of GTP and GDP. Rho-associated kinase (ROCK) is a serine/threonine kinase that acts as an important downstream effector of Rho proteins in the regulation of the cytoskeleton (2) . ROCK has been shown to regulate formation of stress fibers and to control cell migration and contractility of smooth muscle cells by acting on actin filaments. In the kidney, Rho proteins had been identified in the reorganization of stress fibers in opossum kidney proximal tubular cells in response to extracellular acidification. This process is associated with increasing the expression of the Na ϩ /H ϩ exchanger NHE3 and H ϩ -ATPases at the plasma membrane (30 -31) . Thus Rho and some of its downstream effectors are excellent candidates for the regulation of protontransporting proteins at the plasma membrane.
In an elegant study in this issue of AJP-Cell Physiol, the group of Sylvie Breton (21a) (Fig. 1) . These changes in H ϩ -ATPase localization were paralleled by the depolymerization of the actin cytoskeleton.
Polymerization and depolymerization of the actin cytoskeleton is a fast and reversible process regulated by a family of proteins that severe and cap actin. One of these proteins gelsolin is also coexpressed with H ϩ -ATPases both in kidney and epididymis (3, 16) , and previous work from the investigators suggested that gelsolin would regulate H ϩ -ATPase recycling in epididymis clear cells through remodeling the actin cytoskeletion (3). Final proof for this concept, however, would require either specific pharmacological tools affecting gelsolin or the use of gelsolin-deficient mice. The latter exist but no renal or epididymal phenotype has been reported to date (29) .
Several open questions from this and related studies remain to be answered. Do Rho and ROCK II regulate the insertion of new pumps into the membrane, their retrieval, or both? Does this pathway play a role in the assembly or disassembly of pumps or are only assembled pumps trafficked? What are the upstream signals that regulate Rho and ROCK II activity and are these signals involved in regulation of sperm maturation and fertility? These questions are of major relevance to further understanding of mechanisms that regulate one of the major acid extruding pumps at the plasma membrane.
Dysfunction and dysregulation of the proton pump has been linked to various disease processes including infertility, metastasis, and invasion of solid tumors, renal tubular acidosis, or osteoporosis. Rho kinases have attracted much attention over the past years as pharmaceutical targets in hypertension, glaucoma, renal fibrosis, erectile dysfunction, and neurological disease, and a series of ROCK inhibitors has been developed and are undergoing preclinical and clinical testing (2, 10) . Regulation of proton pump activity at the plasma membrane by ROCK may therefore provide new rationales for testing such drugs or as importantly, a call for caution because of unexpected and undesirable side effects.
